Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.87 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705797 | 1.00 | CYP1A2 (0.87) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL424167 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL29463284 | 0.93 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| O-Xylene SCHEMBL7556612 | 0.87 | CYP1A2 (0.87) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL598952 | 0.87 | CYP1A2 (0.65) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL19673857 | 0.84 | CYP1A2 (0.62) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL412050 | 0.84 | ALDH1A1 (0.73) | CYP1A2CYP2A6ALDH1A1TSHRHPGD | |
| SCHEMBL599097 | 0.84 | ALDH1A1 (0.73) | CYP1A2CYP2A6ALDH1A1TSHRHPGD | |
| Formaldehyde SCHEMBL1056693 | 0.84 | CYP1A2 (0.81) | CYP1A2CYP2A6ALDH1A1TSHRACHE | |
| SCHEMBL31001025 | 0.84 | CYP1A2 (0.81) | CYP1A2CYP2A6ALDH1A1TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4091578-B1 | METHOD FOR PRODUCING PLATE DENTURE | TOKUYAMA DENTAL CORP (JP) | 2024-10-09 | — | — | EP | disclosed |
| US-11857385-B2 | Method of producing plate denture, curable composition for stereolithography, and plate denture production kit | TOKUYAMA DENTAL CORPORATION (JP) | 2024-01-02 | — | — | US | disclosed |
| CN-114929158-B | Method for producing denture, curable composition for photoforming, and kit for producing denture | 株式会社德山齿科 | 2023-10-20 | — | — | CN | disclosed |
| US-20230137898-A1 | METHOD OF PRODUCING PLATE DENTURE, CURABLE COMPOSITION FOR STEREOLITHOGRAPHY, AND PLATE DENTURE PRODUCTION KIT | TOKUYAMA DENTAL CORPORATION (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4091578-A1 | METHOD FOR PRODUCING PLATE DENTURE, CURABLE STEREOLITHOGRAPHIC COMPOSITION, AND PLATE DENTURE PRODUCTION KIT | Tokuyama Dental Corporation (JP) | 2022-11-23 | — | — | EP | disclosed |
| CN-114929158-A | Method for producing a denture, curable composition for photo-molding, and kit for producing a denture | 株式会社德山齿科 | 2022-08-19 | — | — | CN | disclosed |
| US-9177819-B2 | Method for manufacturing silicon substrate having textured structure | TOKUYAMA CORPORATION (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140349485-A1 | METHOD FOR MANUFACTURING SILICON SUBSTRATE HAVING TEXTURED STRUCTURE | TOKUYAMA CORPORATION a corporation | 2014-11-27 | — | — | US | disclosed |
| CN-103988313-A | Method for manufacturing silicon substrate having textured structure | TOKUYAMA CORPROATION | 2014-08-13 | — | — | CN | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20040186195-A1 | Photopolymerization initiator and photopolymerizable composition | TOKUYAMA CORPORATION (JP) | 2004-09-23 | — | — | US | disclosed |
| CN-1513884-A | Photopolymerization initiator and composition capable of photopolymerization | 株式会社德山 | 2004-07-21 | — | — | CN | disclosed |
| EP-1431315-A2 | Photopolymerization initiator and photopolymerizable composition | Tokuyama Corporation (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-4740647-A | COPPER ALUMINUM BORATE TO CATALYZE DEHYDROCYCLIZATION OF ALKENYL AROMATIC COMPOUND | AMOCO CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP1A2 810/4885CYP2A6 1101/4885ALDH1A1 645/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CYP1A2 592/4885CYP2A6 1024/4885ALDH1A1 14/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885CYP2A6 1296/4885ALDH1A1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.